Home    Back

Diacerein 1% ointment    (DrugBank: Diacerein)

2 diseases
IDDisease name (Link within this page)Number of trials
36Epidermolysis bullosa15
46Malignant rheumatoid arthritis0

36. Epidermolysis bullosa    [ 147 clinical trials,   170 drugs,   (DrugBank: 40 drugs),   32 drug target genes,   113 drug target pathways]
Searched query = "Epidermolysis bullosa", "EBS", "JEB", "DDEB", "RDEB", "Kindler syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
15 / 147 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2018-000439-29-GB
(EUCTR)		04/06/201822/03/2018A Multi-center Study to Evaluate How CCP-020 (Diacerein 1% ointment) is Absorbed in the Blood and Removed from the Body in Patients with Epidermolysis Bullosa (EB)A Multi-center Study to Evaluate the Pharmacokinetics of Diacerein and Rhein and the Safety of Diacerein after Maximum Use, Topical Administration of CCP-020 (Diacerein 1% ointment) to Patients with Epidermolysis Bullosa (EB) Epidermolysis Bullosa (EB)
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]		Product Name: Diacerein
Product Code: CCP-020
INN or Proposed INN: DIACEREIN		Castle Creek Pharmaceuticals, LLCNULLNot RecruitingFemale: yes
Male: yes		4Phase 1United States;France;Netherlands;Germany;United Kingdom
2NCT03472287
(ClinicalTrials.gov)		May 18, 201814/3/2018To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)A Multi-Center Study to Evaluate the Pharmacokinetics of Diacerein and Rhein and the Safety of Diacerein After Maximum Use, Topical Administration of CCP-020 (Diacerein 1% Ointment) to Patients With Epidermolysis Bullosa (EB)Epidermolysis Bullosa (EB);Epidermolysis Bullosa Simplex;Dystrophic Epidermolysis Bullosa;Junctional Epidermolysis BullosaDrug: Diacerein 1% OintmentCastle Creek Pharmaceuticals, LLCNULLCompleted4 YearsN/AAll11Phase 1United States;France;Netherlands;United Kingdom
3EUCTR2017-003757-41-DE
(EUCTR)		19/04/201821/02/2018An International Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS)An International, Multicenter, Open-label, Long Term Extension Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) Epidermolysis Bullosa Simplex (EBS)
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]		Product Name: Diacerein
Product Code: Diacerein
INN or Proposed INN: DIACEREIN
Other descriptive name: Diacerein		Castle Creek Pharmaceuticals, LLCNULLNot RecruitingFemale: yes
Male: yes		80Phase 2United States;France;Austria;Australia;Israel;Netherlands;Germany;United Kingdom;Italy
4EUCTR2017-003757-41-NL
(EUCTR)		11/04/201806/12/2017An International Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS)An International, Multicenter, Open-label, Long Term Extension Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) Epidermolysis Bullosa Simplex (EBS)
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]		Product Name: Diacerein
Product Code: Diacerein
INN or Proposed INN: DIACEREIN
Other descriptive name: Diacerein		Castle Creek Pharmaceuticals, LLCNULLNot RecruitingFemale: yes
Male: yes		80Phase 2United States;France;Austria;Australia;Israel;Germany;Netherlands;United Kingdom;Italy
5EUCTR2017-003757-41-GB
(EUCTR)		19/02/201813/11/2017An International Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS)An International, Multicenter, Open-label, Long Term Extension Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) Epidermolysis Bullosa Simplex (EBS)
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]		Product Name: Diacerein
Product Code: Diacerein
INN or Proposed INN: DIACEREIN
Other descriptive name: Diacerein		Castle Creek Pharmaceuticals, LLCNULLNot RecruitingFemale: yes
Male: yes		80Phase 2United States;France;Austria;Australia;Israel;Netherlands;Germany;Italy;United Kingdom
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6EUCTR2017-003757-41-FR
(EUCTR)		07/02/201817/10/2018An International Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS)An International, Multicenter, Open-label, Long Term Extension Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) Epidermolysis Bullosa Simplex (EBS)
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]		Product Name: Diacerein
Product Code: Diacerein
INN or Proposed INN: DIACEREIN
Other descriptive name: Diacerein		Castle Creek Pharmaceuticals, LLCNULLNot RecruitingFemale: yes
Male: yes		80Phase 2United States;France;Austria;Australia;Israel;Netherlands;Germany;United Kingdom
7EUCTR2017-003757-41-AT
(EUCTR)		04/01/201829/11/2017An International Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS)An International, Multicenter, Open-label, Long Term Extension Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) Epidermolysis Bullosa Simplex (EBS)
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]		Product Name: Diacerein
Product Code: Diacerein
INN or Proposed INN: DIACEREIN
Other descriptive name: Diacerein		Castle Creek Pharmaceuticals, LLCNULLNot RecruitingFemale: yes
Male: yes		84Phase 2France;United States;Australia;Austria;Israel;Netherlands;Germany;Italy;United Kingdom
8NCT03389308
(ClinicalTrials.gov)		December 1, 201719/12/2017Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa SimplexAn International, Multicenter, Open-label, Long Term Extension Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex (EBS)Epidermolysis Bullosa;Epidermolysis Bullosa SimplexDrug: diacerein 1% ointmentCastle Creek Pharmaceuticals, LLCNULLCompleted6 Months99 YearsAll51Phase 2United States
9EUCTR2016-004427-24-AT
(EUCTR)		10/10/201730/05/2017An International Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS)An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) [DELIVERS Study] Epidermolysis Bullosa Simplex (EBS)
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]		Castle Creek Pharmaceuticals, LLCNULLNot Recruiting Female: yes
Male: yes		80Phase 2France;United States;Australia;Austria;Israel;Netherlands;Germany;Italy;United Kingdom
10EUCTR2016-004427-24-NL
(EUCTR)		06/09/201723/06/2017An International Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS)An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) [DELIVERS Study] Epidermolysis Bullosa Simplex (EBS)
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]		Castle Creek Pharmaceuticals, LLCNULLNot Recruiting Female: yes
Male: yes		80Phase 2France;United States;Austria;Australia;Israel;Germany;Netherlands;Italy;United Kingdom
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
11EUCTR2016-004427-24-DE
(EUCTR)		24/08/201723/05/2017An International Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS)An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) [DELIVERS Study] Epidermolysis Bullosa Simplex (EBS)
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]		Castle Creek Pharmaceuticals, LLCNULLNot Recruiting Female: yes
Male: yes		80Phase 2France;United States;Austria;Australia;Israel;Netherlands;Germany;Italy;United Kingdom
12EUCTR2016-004427-24-GB
(EUCTR)		21/07/201706/07/2017An International Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS)An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) [DELIVERS Study] Epidermolysis Bullosa Simplex (EBS)
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]		Product Name: Diacerein
Product Code: Diacerein
INN or Proposed INN: DIACEREIN
Other descriptive name: Diacerein		Castle Creek Pharmaceuticals, LLCNULLNot RecruitingFemale: yes
Male: yes		80Phase 2France;United States;Austria;Australia;Israel;Netherlands;Germany;Italy;United Kingdom
13NCT03154333
(ClinicalTrials.gov)		June 1, 201710/5/2017Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa SimplexEpidermolysis Bullosa SimplexDrug: diacerein 1% ointment;Drug: A placebo ointmentCastle Creek Pharmaceuticals, LLCNULLTerminated4 YearsN/AAll54Phase 2United States;Australia;Austria;France;Germany;Israel;Netherlands;United Kingdom
14EUCTR2016-004427-24-FR
(EUCTR)		21/08/2017An International Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS)An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) Epidermolysis Bullosa Simplex (EBS)
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]		Castle Creek Pharmaceuticals, LLCNULLNot Recruiting Female: yes
Male: yes		80Phase 2United States;France;Austria;Australia;Israel;Netherlands;Germany;United Kingdom
15EUCTR2018-000439-29-NL
(EUCTR)		27/09/2018A Multi-center Study to Evaluate How CCP-020 (Diacerein 1% ointment) is Absorbed in the Blood and Removed from the Body in Patients with Epidermolysis Bullosa (EB)A Multi-center Study to Evaluate the Pharmacokinetics of Diacerein and Rhein and the Safety of Diacerein after Maximum Use, Topical Administration of CCP-020 (Diacerein 1% ointment) to Patients with Epidermolysis Bullosa (EB) Epidermolysis Bullosa (EB)
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]		Product Name: Diacerein
Product Code: CCP-020
INN or Proposed INN: DIACEREIN		Castle Creek Pharmaceuticals, LLCNULLNAFemale: yes
Male: yes		20Phase 1France;United States;Germany;Netherlands;United Kingdom

Back to top


46. Malignant rheumatoid arthritis    [ 4,183 clinical trials,   2,538 drugs,   (DrugBank: 401 drugs),   183 drug target genes,   219 drug target pathways]
Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: . Trials are sorted by Date_enrollment from most recent to oldest in the table.
0 / 4,183 trial found

Back to top